{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:16:06Z","timestamp":1781244966867,"version":"3.54.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s40261-019-00800-w","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T16:37:49Z","timestamp":1559061469000},"page":"765-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development Strategy and Relative Bioavailability of a Pediatric Tablet Formulation of Ticagrelor"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-5469","authenticated-orcid":false,"given":"Mohammad","family":"Niazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Wissmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders R.","family":"Berggren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Johanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"800_CR1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","volume":"27","author":"S Husted","year":"2009","unstructured":"Husted S, van Giezen JJJ. Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. Cardiovasc Ther. 2009;27:259\u201374.","journal-title":"Cardiovasc Ther"},{"key":"800_CR2","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1111\/j.1538-7836.2009.03527.x","volume":"7","author":"JJJ van Giezen","year":"2009","unstructured":"van Giezen JJJ, Nilsson L, Berntsson P, et al. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost. 2009;7:1556\u201365.","journal-title":"J Thromb Haemost"},{"key":"800_CR3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1074248413511693","volume":"19","author":"D Armstrong","year":"2014","unstructured":"Armstrong D, Summers C, Ewart L, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209\u201319.","journal-title":"J Cardiovasc Pharmacol Ther."},{"key":"800_CR4","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/jth.12360","volume":"11","author":"S Nylander","year":"2013","unstructured":"Nylander S, Femia EA, Scavone M, et al. Ticagrelor inhibits human platelet aggregation via adenosine in addition to P2Y12 antagonism. J Thromb Haemost. 2013;11:1867\u201376.","journal-title":"J Thromb Haemost"},{"key":"800_CR5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/bph.13429","volume":"173","author":"S Nylander","year":"2016","unstructured":"Nylander S, Schulz R. Effects of P2Y12 receptor antagonists beyond platelet inhibition\u2014comparison of ticagrelor with thienopyridines. Br J Pharmacol. 2016;173:1163\u201378.","journal-title":"Br J Pharmacol"},{"key":"800_CR6","unstructured":"Brilinta\u00ae (ticagrelor) prescribing information. AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA. http:\/\/www.azpicentral.com\/brilinta\/brilinta.pdf . Accessed 14 Jan 2018."},{"key":"800_CR7","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/ajh.25273","volume":"93","author":"LL Hsu","year":"2018","unstructured":"Hsu LL, Sarnaik S, Williams S, et al. A dose-ranging study of ticagrelor in children aged 3\u201317\u00a0years with sickle cell disease: a 2-part phase 2 study. Am J Hematol. 2018;93:1493\u2013500.","journal-title":"Am J Hematol"},{"key":"800_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bjh.15646","volume":"184","author":"J Kanter","year":"2019","unstructured":"Kanter J, Abboud MR, Kaya B, et al. Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIb study. Br J Haematol. 2019;184:269\u201378.","journal-title":"Br J Haematol"},{"key":"800_CR9","unstructured":"Heeney MM, Abboud MR, Amilon C, et al. Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). In: Poster presented at the 23rd European Hematology Association Congress, 16 June, 2018; abstract PS1460."},{"key":"800_CR10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1007\/s40265-014-0297-2","volume":"74","author":"F Liu","year":"2014","unstructured":"Liu F, Ranmal S, Batchelor HK, et al. Patient-centred pharmaceutical design to improve acceptability of medicines: similarities and differences in paediatric and geriatric populations. Drugs. 2014;74:1871\u201389.","journal-title":"Drugs."},{"key":"800_CR11","unstructured":"European Medicines Agency. Guideline on pharmaceutical development of medicines for paediatric use. 2011. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/06\/WC500107908.pdf . Accessed 15 Jun 2018."},{"key":"800_CR12","unstructured":"Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof. Patent application. https:\/\/patents.google.com\/patent\/WO2015110952A1\/fi . Accessed 23 May 2019."},{"key":"800_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11096-007-9142-y","volume":"30","author":"DL Hansen","year":"2008","unstructured":"Hansen DL, Tulinius D, Hansen EH. Adolescents\u2019 struggles with swallowing tablets: barriers, strategies and learning. Pharm World Sci. 2008;30:65\u20139.","journal-title":"Pharm World Sci"},{"key":"800_CR14","first-page":"2249","volume":"160","author":"GK Steffensen","year":"1998","unstructured":"Steffensen GK, Pachai A, Pedersen SE. Peroral drug administration to children: are there any problems? [Article in Danish]. Ugeskr Laeger. 1998;160:2249\u201352.","journal-title":"Ugeskr Laeger"},{"key":"800_CR15","unstructured":"AstraZeneca\u2019s policy on bioethics. https:\/\/www.astrazeneca.com\/content\/dam\/az\/our-company\/Documents\/Bioethics%20policy%207.0.pdf . Accessed 23 May 2019."},{"key":"800_CR16","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/j.jchromb.2010.06.018","volume":"878","author":"H Sillen","year":"2010","unstructured":"Sillen H, Cook M, Davis P. Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2010;878:2299\u2013306.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"800_CR17","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence. 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf . Accessed 19 Jun 2018."},{"key":"800_CR18","unstructured":"US Food and Drug Administration. Statistical approaches to establishing bioequivalence. 2001. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070244.pdf . Accessed 19 Jun 2018."},{"key":"800_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1136\/archdischild-2011-300909","volume":"97","author":"D Baguley","year":"2012","unstructured":"Baguley D, Lim E, Bevan A, Pallet A, Faust SN. Prescribing for children\u2014taste and palatability affect adherence to antibiotics: a review. Arch Dis Child. 2012;97:293\u20137.","journal-title":"Arch Dis Child"},{"key":"800_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12887-015-0447-z","volume":"15","author":"JA Mennella","year":"2015","unstructured":"Mennella JA, Roberts KM, Mathew PS, Reed DR. Children\u2019s perceptions about medicines: individual differences and taste. BMC Pediatr. 2015;15:130.","journal-title":"BMC Pediatr."},{"key":"800_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00006454-200101000-00001","volume":"20","author":"RW Steele","year":"2001","unstructured":"Steele RW, Thomas MP, Begue RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J. 2001;20:1\u20135.","journal-title":"Pediatr Infect Dis J."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00800-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00800-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,18]],"date-time":"2022-09-18T19:29:31Z","timestamp":1663529371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00800-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["800"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00800-w","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"28 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are current employees of AstraZeneca.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedure performed in this study were in accordance with the ethical standards of the institution and\/or national research committee and were in compliance with the 1964 Declaration of Helsinki and its later amendments. The local institutional review board or independent ethics committee approved the final protocol and amendment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All subjects provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Data underlying the findings described in this manuscript may be obtained in accordance with AstraZeneca\u2019s data sharing policy described at.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}